Tesofensine
Tesofensine is an oral tablet first developed for Parkinson's and Alzheimer's disease that has shown weight loss effects.
We have not published an audit on Tesofensine. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
It works in the brain by blocking the reuptake of three signaling chemicals: dopamine, norepinephrine, and serotonin, leading to lower appetite and increased resting energy use. [Source: Peptide Dosing Protocols]
Tesofensine works by blocking the brain's recycling of dopamine, norepinephrine, and serotonin, so more of these signals stay active, reducing appetite and slightly increasing the body's resting calorie burn.
Reported side effects
The most commonly reported side effects are dry mouth, nausea, constipation, insomnia, dizziness, and an increased heart rate, with about 20% of participants in the 0.5 mg trial arm stopping due to adverse events.
Who should avoid it
People with heart disease, uncontrolled high blood pressure, psychiatric conditions, or those taking MAO inhibitors, SSRIs, SNRIs, or strong CYP3A4 inhibitors should avoid it, as should pregnant or breastfeeding individuals and anyone under 18.
What gets monitored
Resting heart rate and blood pressure at baseline and regular intervals; body weight and waist circumference; mood, sleep, and anxiety screening, especially in the first few weeks; signs of fluid changes; routine labs (glucose, lipids, electrolytes). [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Tesofensine or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 0.5 mg once daily · Low: 0.25 mg once daily | once daily24 weeks · 24 weeks on | Oral tablet | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: about 9 days. The standard dosing for tesofensine is 0.5 mg taken once daily. |
- once daily24 weeks · 24 weeks on
- Oral tablet
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: about 9 days. The standard dosing for tesofensine is 0.5 mg taken once daily.
Common questions
Is tesofensine FDA approved?
No. As of June 2026, tesofensine is not approved by the FDA for any indication.
What dose of tesofensine was studied in clinical trials?
The two doses most studied are 0.25 mg and 0.5 mg, taken once daily as an oral tablet.
How long does tesofensine take to work?
Some appetite reduction is reported in the first 1-2 weeks, with most weight loss accumulating after 4-6 weeks.
Why does tesofensine have such a long half-life?
Tesofensine is metabolized slowly, leading to steady accumulation for the first month.
What time of day should tesofensine be taken?
Trial protocols generally used morning dosing to avoid sleep disruption.
Does tesofensine raise blood pressure or heart rate?
It raises heart rate in a dose-dependent way, with blood pressure largely unchanged at lower doses.
Can tesofensine be combined with semaglutide or tirzepatide?
No combination trial has been published, and combining appetite suppressants increases risks.
What is the difference between tesofensine, Tesomet, and Nupenta?
Tesofensine is the single active compound; Tesomet includes metoprolol, and Nupenta is a combination product.
Sources
- 01Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet (2008)
- 02Doggrell SA Tesofensine — a novel potent weight loss medicine. Evaluation of Astrup et al. (Lancet 2008). Expert Opinion on Investigational Drugs (2009)
- 03The Lancet Editors Expression of concern — Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. The Lancet (2014)
- 04Lehr T, Staab A, Tillmann C, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. British Journal of Pharmacology (2008)
- 05Appel L, Bergstrom M, Buus Lassen J, Langstrom B Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. European Neuropsychopharmacology (2014)
- 06Saniona AB Saniona's tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial (Viking study). Saniona corporate press release / Euroland Investor (2018)
- 07Saniona AB Saniona's partner Medix receives favorable opinion for tesofensine for the treatment of obesity in Mexico. Saniona / Nasdaq News (2023)
- 08Saniona AB Mexican application for tesofensine not yet approved — Saniona update. Inderes / Saniona (2024)
- 09Perez CI, Luis-Islas J, Lopez A, et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLOS ONE (2024)
- 10Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ Neuropsychiatric adverse effects of centrally acting antiobesity drugs: a systematic review of randomized controlled trials. PMC / Frontiers (2019)
- 11Saniona AB Tesofensine pipeline page. Saniona corporate site (2024)
- 12US Food and Drug Administration Novel Drug Approvals for 2026. FDA.gov (2026)
The reference sections above are imported from our compound knowledge base, which classes the evidence for Tesofensine as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.
Peptide bioregulator referenced for pineal support.